Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 11Brain Neoplasms 6Gliosarcoma 4Glioma 4Oligodendroglioma 3Astrocytoma 3Thyroid Neoplasms 2Spinal Cord Neoplasms 2Ovarian Neoplasms 2Melanoma 2Medulloblastoma 2Lung Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pinealoma 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasms, Mesothelial 1

Interventions

Temozolomide 6Cyclophosphamide 5Magnetic Resonance Spectroscopy 4Carboplatin 4etoposide phosphate 3Thiotepa 3Surgical Procedures, Operative 3Irinotecan 3Filgrastim 3Automobiles 3temsirolimus 2fludarabine 2entinostat 2Vincristine 2Radiotherapy, Conformal 2Proton Therapy 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Isotretinoin 2Granulocyte Colony-Stimulating Factor 2Gadolinium DTPA 2Etoposide 2Donepezil 2Cisplatin 2Celecoxib 2Bevacizumab 2Amplified Fragment Length Polymorphism Analysis 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2trametinib 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pinealoma × Disulfides × CNS × Clear all
NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

National Cancer Institute (NCI)

Phase 2 Completed
108 enrolled 14 charts
CNS

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡